Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

BMY , BMYMP , T.BGU , T.BGC
Sort by: Date|Relevance

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. In a May 13 research note, BTIG analyst Thomas Shrader reported that Gritstone Oncology Inc.'s (GRTS:NASDAQ) lead clinical programs, GRANITE and SL...
Streetwise Reports | May 27, 2019 |

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report. Analyst Ram Selvaraju reported in a July 8 research note that H.C. Wainwright & Co. initiated coverage on Replimune Group Inc. (REPL:NASDAQ) with a Buy ...
Streetwise Reports | July 11, 2019 |

MacDonald Mines building a significant Gold asset near Sudbury

Macdonald Mines Exploration Ltd. (TSX-V: BMK) (US Listing: MCDMF) (Frankfurt: 3M72) is encountering spectacular high-grade gold intercepts on stackings of thick gold zones using a predictive model at its 100%-owned 17,720 hectares SPJ Project, located ~33km SE of Sudbury, On...
James O'Rourke | November 13, 2019 |

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...
Dave Jackson | December 8, 2020 |